We demonstrate that RAF activity supports the expression of BCL-XL and that BCL-XL is a druggable survival factor in hydroxyurea-treated AML and CML cells. This evidence concerns the gene RAF1 and chronic myelogenous leukemia, BCR-ABL1 positive.